408 related articles for article (PubMed ID: 18703382)
1. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
2. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
; Buzdar A; Howell A; Cuzick J; Wale C; Distler W; Hoctin-Boes G; Houghton J; Locker GY; Nabholtz JM
Lancet Oncol; 2006 Aug; 7(8):633-43. PubMed ID: 16887480
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
5. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
7. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
8. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
9. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Buzdar A
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
[TBL] [Abstract][Full Text] [Related]
11. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M; Cuzick J; Howell A; Jackson I;
Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258
[TBL] [Abstract][Full Text] [Related]
13. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
15. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Cella D; Fallowfield L; Barker P; Cuzick J; Locker G; Howell A;
Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
17. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
18. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
19. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
[TBL] [Abstract][Full Text] [Related]
20. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]